Study of KMT2B (MLL2) gene expression changes in patients with breast cancer

IF 0.4 Q4 ONCOLOGY

Breast Cancer Management Pub Date : 2019-10-01 DOI:10.2217/BMT-2018-0016

Mohammad Ghanbari, M. Hosseinpourfeizi, R. Safaralizadeh, A. Aghazadeh, V. Montazeri

引用次数: 2

Abstract

Aim: This study aimed to demonstrate misregulation of KMT2B gene expression in breast cancer tissue. Materials & methods: Cancerous and marginal tissue samples were collected from 43 female patients. After RNA extraction and cDNA synthesis, quantitative-PCR was used to evaluate the expression level of the KMT2B gene. REST, Sigma plot and SPSS software were used to analyze data. Results: KMT2B gene expression was significantly decreased in tumor tissue compared with marginal tissue (p = 0.02). No significant correlation was found between expression levels of KMT2B and clinical parameters of patients (p > 0.05) Conclusion: Our study demonstrated that downregulation of KMT2B is associated with breast cancer and its misregulation may play an important role in tumorigenesis.

查看原文本刊更多论文

乳腺癌患者KMT2B (MLL2)基因表达变化的研究

目的:本研究旨在揭示乳腺癌组织中KMT2B基因表达的失调。材料与方法:43例女性患者的癌组织和边缘组织标本。提取RNA合成cDNA后，采用定量pcr法检测KMT2B基因的表达水平。采用REST、Sigma图和SPSS软件对数据进行分析。结果:KMT2B基因在肿瘤组织中的表达较边缘组织明显降低(p = 0.02)。KMT2B的表达水平与患者的临床参数无显著相关性(p < 0.05)。结论:我们的研究表明，KMT2B的下调与乳腺癌有关，其失调可能在肿瘤发生中起重要作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Breast Cancer Management ONCOLOGY-

CiteScore

0.60

自引率

0.00%

发文量

审稿时长

13 weeks

期刊介绍： Breast Cancer Management (ISSN: 1758-1923) addresses key issues in disease management by exploring the best patient-centered clinical research and presenting this information both directly, as clinical findings, and in practice-oriented formats of direct relevance in the clinic. The journal also highlights significant advances in basic and translational research, and places them in context for future therapy. Breast Cancer Management provides oncologists and other health professionals with the latest findings and opinions on reducing the burden of this widespread disease. Recent research findings and advances clinical practice in the field are reported and analyzed by international experts. The journal presents this information in clear, accessible formats. All articles are subject to independent review by a minimum of three independent experts. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal’s Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP3. Coverage includes: Diagnosis and imaging, Surgical approaches, Radiotherapy, Systemic therapies, Cancer clinical trials, Genetic aspects of disease, Personalized medicine, Translational research and biomarker studies, Management of psychological distress, Epidemiological studies, Pharmacoeconomics, Evidence-based treatment guidelines.